Patients and physicians should be aware that discontinuing GLP‐1 RA therapy may lead to weight regain, which has been observed to consist disproportionately of fat rather than lean mass, potentially exacerbating sarcopenic obesity and worsening outcomes in HF patients.86 Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.